Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the Theravance Biopharma Third Quarter 2025 Conference Call.
Theravance Biopharma Inc. (TBPH)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Madison Avenue Partners Eli Samaha | 9,511,150 | $138,862,790 | 8.29% | |
| 2. | Weiss Asset Management Andrew Weiss | 7,457,060 | $108,873,076 | 1.32% | |
| 3. | Newtyn Management Noah Levy And Eugene Dozortsev | 4,950,000 | $72,270,000 | 8.85% | |
| 4. | Irenic Capital Management Adam Katz And Andy Dodge | 2,760,948 | $40,309,841 | 4.22% | |
| 5. | Park West Asset Management Peter S. Park | 1,284,081 | $18,747,583 | -29% | 1.58% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.80 | 999,800 | $7,798,440.00 | 9,511,150 | 2024-08-07 | Filing | |
| $8.75 | 499,324 | $4,369,085.00 | 8,511,350 | 2024-05-01 | Filing | |
| $8.75 | 999,800 | $8,748,250.00 | 8,012,026 | 2024-05-01 | Filing | |
| $22.54 | 1,000 | $22,540.00 | 56,757 | 2018-05-21 | Filing | |
| $26.34 | 4,000 | $105,358.80 | 213,180 | 2017-08-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.75 | 15,534 | $291,251.63 | 277,695 | 2025-12-03 | Filing | |
| $18.75 | 7,766 | $145,618.71 | 293,229 | 2025-12-03 | Filing | |
| $18.75 | 7,767 | $145,630.47 | 300,995 | 2025-12-03 | Filing | |
| $20.00 | 15,501 | $310,020.00 | 44,703 | 2025-11-26 | Filing | |
| $20.00 | 14,000 | $280,000.00 | 60,204 | 2025-11-26 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,068,994 | $59,407,312 | 0% | |
| 2. | 2,211,582 | $32,289,097 | 0% | |
| 3. | 1,055,905 | $15,416,213 | 0% | |
| 4. | 897,990 | $13,113,478 | 0% | |
| 5. | 766,704 | $11,193,148 | 0% |
News See All
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the Theravance Biopharma Second Quarter 2025 Conference Call.
Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma
Viatris Inc. (NASDAQ:VTRS) is one of the best low priced pharma stocks to buy now.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2025 Earnings Call Transcript
Operator: Hello, ladies and gentlemen. Good afternoon. I would like to welcome everyone to the Theravance Biopharma First Quarter 2025 Conference Call.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2024 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2024 Earnings Call Transcript February 26, 2025Theravance Biopharma, Inc. misses on earnings expectations.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, good afternoon. I would like to welcome everyone to the Theravance Biopharma Third Quarter 2024 Conference Call.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2024 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2024 Earnings Call Transcript August 5, 2024Theravance Biopharma, Inc. misses on earnings expectations.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the Theravance Biopharma First Quarter 2024 Conference Call.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call Transcript
Theravance Biopharma, Inc. beats earnings expectations. Reported EPS is $0.03, expectations were $-0.04.
Billionaire Seth Klarman’s Biotech Stock Picks
In this article, we discuss billionaire Seth Klarman’s biotech stock picks.
Hedge Fund Resource Center Billionaire Hedge Funds
